BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27143871)

  • 1. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
    Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
    Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of N-Acetylcysteine for Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
    Zhang L; Xiong Y; Du L
    Biomed Res Int; 2022; 2022():9133777. PubMed ID: 35795313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Beeh KM; Beier J; Candler H; Wittig T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
    Schermer T; Chavannes N; Dekhuijzen R; Wouters E; Muris J; Akkermans R; van Schayck O; van Weel C
    Respir Med; 2009 Apr; 103(4):542-51. PubMed ID: 19138505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
    Cazzola M; Calzetta L; Page C; Jardim J; Chuchalin AG; Rogliani P; Matera MG
    Eur Respir Rev; 2015 Sep; 24(137):451-61. PubMed ID: 26324807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections.
    Blasi F; Page C; Rossolini GM; Pallecchi L; Matera MG; Rogliani P; Cazzola M
    Respir Med; 2016 Aug; 117():190-7. PubMed ID: 27492531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
    Tse HN; Raiteri L; Wong KY; Yee KS; Ng LY; Wai KY; Loo CK; Chan MH
    Chest; 2013 Jul; 144(1):106-118. PubMed ID: 23348146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of oral N-acetylcysteine on COPD patients with microsatellite polymorphism in the heme oxygenase-1 gene promoter.
    Zhang JQ; Zhang JQ; Fang LZ; Liu L; Fu WP; Dai LM
    Drug Des Devel Ther; 2015; 9():6379-87. PubMed ID: 26674585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
    Decramer M; Rutten-van Mölken M; Dekhuijzen PN; Troosters T; van Herwaarden C; Pellegrino R; van Schayck CP; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
    Lancet; 2005 Apr 30-May 6; 365(9470):1552-60. PubMed ID: 15866309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
    Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
    Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China.
    Tian H; Zhou Y; Tang L; Wu F; Deng Z; Lin B; Huang P; Wei S; Zhao D; Zheng J; Zhong N; Ran P
    Trials; 2020 Sep; 21(1):780. PubMed ID: 32917271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.
    Zhang JQ; Zhang JQ; Liu H; Zhao ZH; Fang LZ; Liu L; Fu WP; Shu JK; Feng JG; Dai LM
    Int J Chron Obstruct Pulmon Dis; 2015; 10():917-23. PubMed ID: 25999707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses.
    Papi A; Alfano F; Bigoni T; Mancini L; Mawass A; Baraldi F; Aljama C; Contoli M; Miravitlles M
    Arch Bronconeumol; 2024 May; 60(5):269-278. PubMed ID: 38555190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of OM-85 in Patients with Chronic Bronchitis and/or Chronic Obstructive Pulmonary Disease.
    Tang H; Fang Z; Saborío GP; Xiu Q
    Lung; 2015 Aug; 193(4):513-9. PubMed ID: 26044556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral
    Hirai DM; Jones JH; Zelt JT; da Silva ML; Bentley RF; Edgett BA; Gurd BJ; Tschakovsky ME; O'Donnell DE; Neder JA
    J Appl Physiol (1985); 2017 May; 122(5):1351-1361. PubMed ID: 28255088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antioxidant treatment with N-acetylcysteine and vitamin C in patients with chronic bronchitis].
    Lukas R; Schärling B; Schultze-Werninghaus G; Gillissen A
    Dtsch Med Wochenschr; 2005 Mar; 130(11):563-7. PubMed ID: 15761783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials.
    Grandjean EM; Berthet P; Ruffmann R; Leuenberger P
    Clin Ther; 2000 Feb; 22(2):209-21. PubMed ID: 10743980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.